Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI

Jan 13, 2025 - financialpost.com
Rakovina Therapeutics Inc., a biopharmaceutical company, has announced a significant milestone in its collaboration with Variational AI. The partnership has successfully identified AI-generated molecules targeting ATR (Ataxia Telangiectasia and Rad3-related protein) with designs for central nervous system (CNS) penetration. These molecules are intended to advance cancer treatment by selectively inducing cancer cell death and improving therapeutic outcomes. The collaboration utilizes Variational AI’s Enki™ platform to expedite the discovery of innovative inhibitors for DNA damage response (DDR) kinase targets, significantly reducing drug discovery timelines.

The shortlisted ATR-targeted inhibitors will proceed to chemical synthesis and preclinical validation, marking a critical step in addressing unmet medical needs in oncology. This achievement highlights the transformative potential of AI in accelerating drug development and innovation in cancer therapy. Rakovina aims to expand its research scope with Variational AI to target additional DDR kinase pathways, building a comprehensive pipeline of next-generation small-molecule therapies. The collaboration, announced in September 2024, combines Rakovina’s oncology expertise with Variational AI’s computational modeling capabilities to enhance drug candidate selection and reduce discovery timelines.

Key takeaways:

  • Rakovina Therapeutics has achieved a milestone in developing AI-generated molecules targeting ATR for CNS penetration, advancing cancer drug innovation.
  • The collaboration with Variational AI uses the Enki™ platform to fast-track the discovery of innovative inhibitors for DNA damage response kinase targets.
  • The shortlisted ATR-targeted inhibitors will proceed to chemical synthesis and preclinical validation, aiming to address unmet medical needs in oncology.
  • Rakovina's partnership with Variational AI aims to build a comprehensive pipeline of next-generation small-molecule therapies, leveraging AI for faster drug development.
View Full Article

Comments (0)

Be the first to comment!